If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
42.40    0.00 (0.00%)
Bid:
41.40
Ask:
43.40
Spread: 2.00 (4.831%)
Market Cap: £66.18m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Issue of Equity

2 Jun 2023 09:41

RNS Number : 5005B
Maven Income and Growth VCT 3 PLC
02 June 2023
 

Maven Income and Growth VCT 3 PLC (the Company)

 

Issue of Equity

 

On 7 October 2022, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £5 million, with an over-allotment facility for up to a further £5 million (the Offer).

 

Pursuant to the Offer, £819,220 of valid applications were received in the period from 7 October 2022 up to 12 noon on 26 May 2023 in respect of the 2023/2024 tax year. This is the first and final allotment in respect of the 2023/2024 tax year and, as a result, the Company has issued and allotted 1,441,593 new Ordinary Shares on 2 June 2023. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which these shares were issued were in the range of 56.27p to 57.18p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 115,358,633. Therefore, the total number of voting rights in the Company is 115,358,633.

 

The total funds raised by the Company for the 2022/2023 and the 2023/2024 tax years is £6,752,600.

 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares so issued to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence on or around 6 June 2023.

 

The above statement of Voting Capital may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

2 June 2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFIFVTRAIFIIV
Date   Source Headline
23rd Mar 20225:05 pmRNSIssue of Equity
21st Mar 20222:59 pmRNSPublication of Suppl.Prospcts
11th Mar 202211:35 amRNSIssue of Equity - Dividend Investment Scheme
10th Mar 202211:30 amRNSIssue of Equity
10th Mar 202211:20 amRNSStatement re Dividend Investment Scheme
7th Mar 20226:32 pmRNSAnnual Financial Report
22nd Feb 20222:27 pmRNSTransaction in Own Shares
18th Feb 20225:48 pmRNSIssue of Equity - Replacement Announcement
7th Feb 20221:53 pmRNSDirector/PDMR Shareholding
7th Feb 20221:52 pmRNSDirector/PDMR Shareholding
7th Feb 20221:50 pmRNSDirector/PDMR Shareholding
7th Feb 20221:48 pmRNSDirector/PDMR Shareholding
7th Feb 20221:47 pmRNSDirector/PDMR Shareholding
7th Feb 20221:46 pmRNSDirector/PDMR Shareholding
7th Feb 202210:50 amRNSIssue of Equity
4th Feb 20229:45 amRNSStatement re NAV and Final Dividend
31st Jan 20224:25 pmRNSStatement re Offer for Subscription
10th Jan 202212:43 pmRNSStatement re Offer for Subscription
5th Jan 202210:35 amRNSDividend Declaration
24th Nov 20214:45 pmRNSTransaction in Own Shares
29th Oct 202112:44 pmRNSNet Asset Value(s)
20th Oct 20214:46 pmRNSResult of General Meeting
20th Sep 20215:21 pmRNSPublication of a Prospectus
20th Sep 20214:57 pmRNSStatement re Change of Registrar
10th Sep 202112:34 pmRNSIssue of Equity
7th Sep 20213:08 pmRNSStatement re Dividend Investment Scheme
16th Aug 20214:08 pmRNSTransaction in Own Shares
13th Aug 20212:13 pmRNSHalf-year Report
5th Aug 20214:39 pmRNSTransaction in Own Shares
3rd Aug 202111:31 amRNSStatement re NAV and Interim Dividend
16th Jun 20213:16 pmRNSStatement re Offer for Subscription
16th Apr 202110:25 amRNSIssue of Equity
15th Apr 20214:30 pmRNSTransaction in Own Shares
13th Apr 20212:22 pmRNSStatement re Dividend Investment Scheme
12th Apr 20219:00 amRNSNet Asset Value(s)
7th Apr 202112:28 pmRNSResult of AGM
5th Mar 20214:39 pmRNSFinal Results
29th Jan 20212:55 pmRNSTransaction in Own Shares
22nd Jan 20213:17 pmRNSNAV and Proposed Final Dividend
17th Nov 20204:29 pmRNSTransaction in Own Shares
16th Nov 20204:55 pmRNSTransaction in Own Shares
11th Nov 20204:58 pmRNSNet Asset Value(s)
28th Aug 202010:28 amRNSIssue of Equity
26th Aug 20205:23 pmRNSTransaction in Own Shares
21st Aug 20204:10 pmRNSStatement re NAV and DIS
29th Jul 20204:45 pmRNSTransaction in Own Shares
28th Jul 20204:44 pmRNSTransaction in Own Shares
24th Jul 20203:23 pmRNSHalf-year Report
9th Jul 202010:00 amRNSIssue of Equity
29th Jun 20205:25 pmRNSStatement re NAV and Interim Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.